For research use only. Not for therapeutic Use.
PNU-177864 is a potent, selective and orally active dopamine D3 receptor antagonist. PNU-177864 is structurally consistent with a cationic amphiphilic agent (CAD) and induces phospholipidosis in vivo. PNU-177864 antischizophrenic activity[1][2].
PNU-177864 (12.5-200 mg/kg; oral gavage; daily; for 2-4 weeks; Sprague-Dawley rats) treatment induces phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles[1].
| Catalog Number | I010751 |
| CAS Number | 250266-51-4 |
| Synonyms | N-[4-[2-(propylamino)ethyl]phenyl]-4-(trifluoromethoxy)benzenesulfonamide |
| Molecular Formula | C18H21F3N2O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C18H21F3N2O3S/c1-2-12-22-13-11-14-3-5-15(6-4-14)23-27(24,25)17-9-7-16(8-10-17)26-18(19,20)21/h3-10,22-23H,2,11-13H2,1H3 |
| InChIKey | JGGQWSXZZQPZTR-UHFFFAOYSA-N |
| SMILES | CCCNCCC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F |
| Reference | [1]. Rudmann DG, et al. Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864. Toxicol Pathol. 2004 May-Jun;32(3):326-32. [2]. Vonderfecht SL, et al. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol. 2004 May-Jun;32(3):318-25. |
